Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207855 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5210653 | 0.88 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL7487002 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5210855 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7486869 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5208074 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7484348 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5205192 | 0.85 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL7486750 | 0.83 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL4575852 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| EP-1377298-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | claimed |
| EP-0863891-B1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2002-12-11 | — | — | EP | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002072106-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS WITH EXEMESTANE | PHARMACIA ITALIA SPA (IT) | 2002-09-19 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | claimed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | claimed |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM IP INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20230202964-A1 | CANNABIGEROLIC ACID (CDGA) DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| US-20230192588-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| EP-4161901-A1 | CANNABIGEROLIC ACID (CBGA) DERIVATIVES AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161900-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2023-04-12 | — | — | EP | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| US-5789413-A | ANTIINFLAMMATORY AGENT | MERCK FROSST CANADA, INC. (CA) | 1998-08-04 | — | — | US | disclosed |
| US-5698584-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-12-16 | — | — | US | disclosed |
| WO-1997028121-A1 | ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192588-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | CNR2, CNR1, GPR18 | PTGS2 1908/4885PTGS1 1885/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PTGS2 4/4885PTGS1 6/4885 |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | TNF, PTGS1, MIF | PTGS2 4/4885PTGS1 2/4885 |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | TNF, PTGES2, PTGS2 | PTGS2 3/4885PTGS1 4/4885 |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FAAH | PTGS2 2555/4885PTGS1 2010/4885 |
| US-20230202964-A1 | CANNABIGEROLIC ACID (CDGA) DERIVATIVES AND USES THEREOF | CNR2, CNR1, GPR18 | PTGS2 411/4885PTGS1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.